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Chronic granulomatous disease (CGD) is a primary immu-
nodeficiency caused by a defect in production of phagocyte-
derived reactive oxygen species, which leads to recurrent 
infections with a characteristic group of pathogens not pre-
viously known to include methylotrophs. Methylotrophs are 
versatile environmental bacteria that can use single-carbon 
organic compounds as their sole source of energy; they 
rarely cause disease in immunocompetent persons. We 
have identified 12 infections with methylotrophs (5 reported 
here, 7 previously reported) in patients with CGD. Methy-
lotrophs identified were Granulibacter bethesdensis (9 
cases), Acidomonas methanolica (2 cases), and Methylo-
bacterium lusitanum (1 case). Two patients in Europe died; 
the other 10, from North and Central America, recovered 
after prolonged courses of antimicrobial drug therapy and, 
for some, surgery. Methylotrophs are emerging as disease-
causing organisms in patients with CGD. For all patients, 
sequencing of the 16S rRNA gene was required for correct 
diagnosis. Geographic origin of the methylotroph strain may 
affect clinical management and prognosis.
Chronic granulomatous disease (CGD) is a primary im-munodeficiency characterized by recurrent infections 
of the lung, skin, lymph nodes, and liver, as well as granu-
lomatous inflammation affecting those organs and hollow 
viscera. The immunodeficiency results from deficiencies in 
any 1 of the 5 subunits forming the NADPH (nicotinamide 
adenine dinucleotide phosphate) oxidase 2 (Nox2)–based 
complex, which leads to impaired production of reactive 
oxygen species in phagocytes. Defects in the Nox2 (gp-
91phox) enzymatic subunit (CYBB [cytochrome b-245, β 
polypeptide]) are inherited in an X-linked manner, whereas 
defects in subunits p47phox (NCF1 [neutrophil cytosolic fac-
tor 1]), p22phox (CYBA [cytochrome b-245, α polypeptide]), 
p67phox (NCF2 [neutrophil cytosolic factor 2]), and p40phox 
(NCF4 [neutrophil cytosolic factor 4]) are inherited in an 
autosomal recessive manner (1,2).
CGD infections are often caused by a characteristic 
group of pathogens, including Staphylococcus aureus, 
Serratia marcescens, Burkholdheria cepacia complex, 
Nocardia spp., and Aspergillus spp. (1). However, new 
pathogens are emerging, and some reportedly are found 
almost exclusively in patients with CGD. Methylotrophs 
are bacteria that can use single-carbon organic compounds 
as their sole source of energy, the widespread availability 
of which makes these organisms versatile environmental 
inhabitants. However, they rarely cause disease in immu-
nocompetent persons (3).
We previously reported 7 methylotroph infections in 
patients with CGD and here describe 5 more (Table). From 
these 12 infections, we have isolated the methylotrophs 
Granulibacter bethesdensis, Acidomonas methanolica, and 
Methylobacterium lusitanum. These infections were difficult 
to diagnose and required prolonged courses of antimicrobial 
drugs and sometimes surgery for complete resolution.
Patient 1
In 2008, a 1-year-old girl from Mexico who had p67phox-
deficient CGD was examined for fever, weight loss, and 
enlarged cervical lymph nodes; she had been receiving 
ceftriaxone, clindamycin, itraconazole, and interferon-γ 
for treatment of CGD. CGD was diagnosed when she was 
6 months of age, at which time she had Penicillium sp. 
pneumonia and an abnormal dihydrorhodamine oxidation 
assay result. At 3 weeks of age, she had had a methicillin-
sensitive S. aureus labial abscess, followed at 8 months 
of age by 3 episodes of pneumonia and an S. marcescens 
buttock abscess.
A computed tomographic (CT) scan performed at the 
time of admission showed cervical, mediastinal, and mes-
enteric lymphadenopathy and a right middle lung lobe in-
filtrate and hepatosplenomegaly. Excisional cervical lymph 
node and lung biopsy samples were processed for bacterial, 
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nocardial, fungal, and mycobacterial cultures and staining. 
Direct Gram staining revealed moderate mononuclear cells 
but no organisms. After 11 days of incubation on chocolate 
agar at 37°C, the lung biopsy culture grew 1 pink colony. 
Species level identification conducted by full 16S rRNA 
gene sequencing (≈1,500 bp) showed a 99.8% match to the 
M. lusitanum type strain (7). Etest (bioMérieux Diagnos-
tics, Marcy l’Etoile, France) showed the following MICs 
(in μg/mL): amikacin (MIC = 4), cefepime (MIC = 8), cef-
triaxone (MIC = 2), ciprofloxacin (MIC = 16), piperacillin-
tazobactam (MIC = 2), imipenem (MIC = 2), meropenem 
(MIC ≥32), trimethoprim/sulfamethoxazole (MIC >32), 
and aztreonam (MIC >256). Culture of the cervical lymph 
node biopsy sample grew S. marcescens.
After 7 months of treatment with ceftriaxone, clindamy-
cin, and itraconazole, the patient completely recovered from 
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Table. Summary of methylotroph infections in patients with chronic granulomatous disease* 
Patient no., 
reference 
Patient 
age, y/sex CGD genetics† Clinical findings 
Microbiological 
findings Treatment‡ Outcome 
1  
(this study) 
1/F Autosomal 
recessive (NCF2 
c.304C>T; 
p.R102X) 
Pneumonia, 
cervical 
lymphadenitis 
Methylobacterium 
lusitanum (lung), 
Serratia marcescens 
(lymph node) 
CRO/CLI/ITZ, HSCT Recovered 
2  
(this study) 
19/M X-linked 
(CYBB intragenic 
deletion) 
Necrotizing 
cervical 
lymphadenitis 
Granulibacter 
bethesdensis; 
Staphylococcus 
epidermidis 
VAN/CRO, CFD/DOX/RIF Recovered 
3  
(this study)  
16/M X-linked 
(CYBB 13-exon 
deletion) 
Meningitis G. bethesdensis MEM/CIP/AMK/DOX/TEC/VCZ, 
MEM/CIP/AMK/DOX/CSP/ 
LAMB/LZD/RIF/INH/CLR 
Died 
4  
(this study) 
9/M X-linked 
(CYBB point 
mutation; exon 
10) 
Cervical abscess, 
lymphadenitis 
Acidomonas 
methanolica 
TZP/VAN/LAMB/CIP, 
MEM/VAN/LAMB/CIP, 
CIP/VCZ/TMPSMX/ IFN-γ, 
HSCT 
Recovered 
5  
(this study)  
36/M X-linked 
(CYBB c.1139 
G>A; p.W380X) 
Multifocal 
lymphadenitis 
G. bethesdensis; 
S. epidermidis 
VAN/CRO, 
CRO/DOX/TMPSMX/ITZ 
Still 
receiving 
treatment 
as of 2015 
6 (4) 10/M X-linked 
(CYBB 
p.Arg226X) 
Necrotizing 
cervical 
lymphadenitis 
A. methanolica TMPSMX/CRO/DOX, 
TMPSMX/RFB/GEN 
Recovered 
7 (5) 10/M X-linked Bacteremia G. bethesdensis TMPSMX/CAZ/MTZ/LZD/VCZ Died 
8 (6) 39/M X-linked Necrotizing 
cervical, 
mediastinal, 
axillary 
lymphadenitis 
G. bethesdensis MEM/DOX, CRO/DOX  
9 (6) 36/M X-linked Multifocal 
necrotizing 
lymphadenitis, 
splenic lesions, 
ascites 
G. bethesdensis MEM/TMPSMX/ITZ, 
MEM/TMPSMX/VCZ/TOB, 
CRO/TMPSMX/IFN-γ, 
CPD/DOX/TMPSMX/IFN-γ, 
splenectomy/TGC 
Recovered 
10 (6) 13/M X-linked Necrotizing 
thoracic 
lymphadenitis 
G. bethesdensis, 
S. epidermidis, 
Candida glabrata, 
Streptococcus mitis 
group 
MEM/VCZ, 
CRO/TOB/DOX/VCZ, CRO, 
DOX, CRO, CFD 
Recovered 
11 (6) 17/M X-linked Necrotizing 
cervical and 
mediastinal 
lymphadenitis 
G. bethesdensis LVX, DOX, lymph node excision Recovered 
12 (6) 37/M X-linked Necrotizing 
supraclavicular 
lymphadenitis, 
splenic and liver 
lesions 
G. bethesdensis CRO/GEN/VAN, 
CRO/DOX/TMPSMX, 
CFD/DOX/TMPSMX, 
DOX/TMPSMX 
Recovered 
*AMK, amikacin; CAZ, ceftazidime; CFD, cefdinir; CGD, chronic granulomatous disease; CLI, clindamycin; CLR, clarithromycin; CIP, ciprofloxacin; CPD, 
cefpodoxime; CRO, ceftriaxone; CSP, caspofungin; CYBB, cytochrome b-245, β polypeptide; DOX, doxycycline; GEN, gentamicin; HSCT, hematopoietic 
stem cell transplant; IFN-γ, interferon- γ; INH, isoniazid; ITZ, itraconazole; LAMB, liposomal amphotericin B; LVX, levofloxacin; LZD, linezolid; MEM, 
meropenem; MTZ, metronidazole; NCF2, neutrophil cytosolic factor 2; RFB, rifabutin; RIF, rifampin; TEC, teicoplanin; TGC, tigecycline; TMPSMX,  
trimethoprim/sulfamethoxazole; TOB, tobramycin; VAN, vancomycin; VRZ, voriconazole. 
†Information in parentheses indicates, when known, the mutation that led to CGD. 
‡Slashes separate drugs in the same regimen; commas separate regimens. 
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the pneumonia and cervical lymphadenitis. She subsequent-
ly underwent successful hematopoietic stem cell transplant.
Patient 2
In 2011, a 19-year-old white man from Ohio, USA, who 
had X-linked CGD was examined for right neck swelling 
and tenderness (2 weeks’ duration), a yellow ulcerated le-
sion on the right side of the hard palate, and an enlarged 
right tonsil with copious exudate. He had been receiving 
prophylactic trimethoprim-sulfamethoxazole and posacon-
azole. Erythrocyte sedimentation rate (ESR) was 28 mm/h, 
and C-reactive protein (CRP) concentration was 82 mg/L.
CGD had been diagnosed at birth on the basis of a 
positive family history. The patient had had hydrocepha-
lus, catheter-associated fungal meningitis, and Aspergillus 
fumigatus pneumonia. When he was 15 years of age, CGD 
proctitis developed. Fourteen months before hospital ad-
mission, he had undergone right neck dissection for Ro-
thia aeria infection, which was successfully treated with 
β-lactams (8).
CT images showed new bulky lymphadenopathy in the 
right neck, involving all nodal planes, and increased thick-
ening and asymmetry of the right oropharynx with hypoat-
tenuation of the right palatine tonsils. Culture of the right 
tonsillar exudate and empirical treatment with meropenem 
were not helpful. Antimicrobial therapy was switched to 
ceftriaxone and high-dose penicillin for empirical cover-
age of G. bethesdensis and Actinomyces spp. Right neck 
dissection with tonsillectomy yielded Staphylococcus epi-
dermidis, and full 16S rRNA gene sequencing (≈1,500 bp) 
of 1 colony of a gram-negative bacillus showed a 99.8% 
match to the G. bethesdensis type strain. Nine weeks of 
vancomycin and ceftriaxone followed by 8 weeks of cef-
dinir, doxycycline, and rifampin led to complete resolution 
of the lymphadenitis.
Patient 3
In 2012, a 16-year-old boy from Portugal who had X-
linked CGD was examined for fever, cervical lymphade-
nopathy, and elevated inflammatory markers. CT images 
showed a deep cervical abscess, from which nothing grew 
on culture but which completely resolved after 5 weeks of 
intravenous ceftriaxone, doxycycline, and ciprofloxacin 
and 6 weeks of oral amoxicillin/clavulanate, ciprofloxa-
cin, and doxycycline, along with prophylactic itracon-
azole and interferon-γ.
Immediately after completion of that course of anti-
microbial drugs, pneumonia with pleural effusions devel-
oped. Results of all cultures (blood, lymph node, bron-
cheoalveolar lavage, and pleural fluid) were negative, but 
full 16S rRNA gene sequencing (≈1,500 bp) of pleural 
fluid showed a >99% match to Cupriavidus spp. The 
patient received meropenem, ciprofloxacin, amikacin, 
doxycycline, teicoplanin, and voriconazole. Two weeks 
later, fever with splenomegaly, pancytopenia, low fibrino-
gen levels, and elevated ferritin and soluble CD25 levels 
were noted. Interferon-γ prophylaxis was discontinued 
and the patient was administered dexamethasone and 
intravenous immunoglobulin, after which the presumed 
exuberant inflammatory response quickly resolved. CT 
images of the neck and lung were unremarkable, as were 
positron emission tomography images. 
A month later, the boy was examined for fever, cough, 
and altered mental status; he required intubation and trans-
fer to the intensive care unit. Magnetic resonance imaging 
revealed bilateral pneumonia and multiple intraparenchy-
mal brain abscesses. Cerebrospinal fluid (CSF) was unre-
markable. A lung biopsy sample, collected while the pa-
tient was receiving meropenem, ciprofloxacin, amikacin, 
doxycycline, teicoplanin, and voriconazole, was sterile. 
Voriconazole was switched to caspofungin and liposomal 
amphotericin B, and teicoplanin was switched to linezolid. 
The patient eventually recovered and was transferred out of 
the intensive care unit.
One month later, fever with focal neurologic deficits 
developed. CSF examination confirmed persistent pleo-
cytosis with low glucose and elevated protein levels, and 
CT images indicated leptomeningitis. A 4-day culture of 
CSF on chocolate agar showed brownish colonies 1–2 mm 
in diameter. Full 16S rRNA gene sequencing (≈1,500 bp) 
performed on the isolate from CSF showed a 99.7% match 
to the G. bethesdensis type strain. Etest showed the follow-
ing MICs (in μg/mL): tobramycin (MIC = 12), ceftriaxone 
(MIC >32), doxycycline (MIC = 24), and trimethoprim/
sulfamethoxazole (MIC = 0.25). Isoniazid, clarithromycin, 
and rifampin had already been added to the patient’s treat-
ment regimen. Despite the above interventions, the patient 
died of obstructive hydrocephalus and multiorgan failure.
Patient 4
In 2013, a 9-year-old multiracial boy from Iowa, USA, who 
had X-linked CGD was examined for a 1-day history of 
fever, fatigue, decreased appetite, headache, and neck pain. 
He had been receiving oral trimethoprim/sulfamethoxa-
zole, voriconazole and interferon-γ for CGD prophylaxis. 
When he was 1 month of age, he had had disseminated 
Candida lusitaniae infection with retropharyngeal, para-
pharyngeal, hepatic, and splenic abscesses. At 6 months of 
age, he was hospitalized for a progressively enlarging left 
posterior neck mass. A lymph node biopsy sample showed 
necrotizing granulomata and rare yeast forms suggestive 
of Histoplasma, but no specific organism was identified. 
He also had recurrent otitis media, tonsillitis, and aphthous 
stomatitis. Two months before the visit reported here, he 
had had Aspergillus versicolor pneumonia complicated by 
granulomatous appendicitis.
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At the time of this hospital admission, he had 2 en-
larged right anterior cervical nodes, which were soft, mo-
bile, and not tender. ESR was 41 mm/h, and CRP concen-
tration was 76 mg/L. CT images showed a 23 × 9 × 18-mm 
abscess adjacent to the right sternocleidomastoid muscle, 
extensive left supraclavicular lymphadenopathy, and left-
sided pneumonia and pleural effusion.
Excisional biopsy of the right cervical lymph nodes 
yielded pus but no organisms. After 3 days of culture on 
chocolate agar, ≈20 tan colonies of an aerobic gram-neg-
ative bacillus were seen. The organism was oxidase-pos-
itive, catalase-positive, and indole-negative. After 6 days, 
abundant growth of a morphologically identical organ-
ism was seen on potato dextrose agar without antimicro-
bial agent and on Mycosel agar with chloramphenicol and 
cycloheximide but not on brain heart infusion agar with 
chloramphenicol and gentamicin (all media from Remel, 
Lenexa, KS, USA). Matrix-assisted laser desorption/ion-
ization–time of flight mass spectrometry (Biotyper system 
version 3.1; Bruker Daltonics Inc., Billerica, MA, USA) 
from directly smeared colonies with and without formic 
acid overlay (9) yielded no identification, and growth was 
insufficient for biochemical identification or susceptibil-
ity testing. Species-level identification conducted by 16S 
rRNA gene sequencing (ABI MicroSeq 500 kit; Thermo 
Fisher Scientific, Grand Island, NY, USA, and the IDNS 
SmartGene system, version 3.6.10; SmartGene Inc., Ra-
leigh, NC, USA) was interpreted as A. methanolica (100% 
identity >388 bp with type strain CGDAM1) (7). No other 
pathogens were grown or amplified from any specimen.
The patient initially received piperacillin/tazobactam 
and vancomycin; liposomal amphotericin B was adminis-
tered in view of his recent A. versicolor pneumonia. After 4 
days, the piperacillin/tazobactam was switched to merope-
nem and ciprofloxacin was added. Levels of inflammatory 
markers eventually returned to reference values, and the 
lymphadenopathy improved after 5 weeks of intravenous 
meropenem and intravenous and oral ciprofloxacin. The 
patient was discharged with ciprofloxacin, voriconazole for 
A. versicolor pneumonia, prophylactic trimethoprim/sulfa-
methoxazole, and interferon-γ. He subsequently underwent 
successful transplant of matched unrelated hematopoietic 
stem cells.
Patient 5
In 2014, a 36-year-old white man from Georgia, USA, 
who had X-linked CGD was hospitalized with cervical 
and abdominal lymphadenopathy; he had 1-year history of 
fever, malaise, and weight loss. X-linked CGD had been 
diagnosed when the patient was 6 months of age, when he 
had had hepatosplenomegaly, cervical lymphadenitis, and 
recurrent S. aureus infections. Aspergillus spp. pneumo-
nia developed when he was 2 years of age, a liver abscess 
required incision and drainage when he was 4 years of age, 
and multiple abdominal abscesses required surgery when 
he was 6 years of age. Prophylactic trimethoprim/sulfa-
methoxazole for CGD had been effective until the hospital-
ization reported here.
A year before admission, the patient had experienced 
sudden onset of fever, cough, and shortness of breath. 
Right-sided pleural effusion was treated with antimicrobial 
drugs and thoracentesis. Cough and dyspnea improved, but 
fever, fatigue, malaise, myalgia, and weight loss of >15 kg 
were refractory to hydroxychloroquine and interferon-γ. 
At 2 months before admission, he had had cervical and 
abdominal lymphadenopathy with ascites. Peritoneal fluid 
examination, esophagogastroduodenoscopy, and colonos-
copy were not informative. Excisional biopsy of a right 
posterior cervical lymph node, tuberculin skin testing, and 
QuantiFERON–TB Gold (QIAGEN, Valencia, CA, USA) 
testing produced negative results. Ciprofloxacin and metro-
nidazole did not abate symptoms and fever.
At admission, the patient had right supraclavicular and 
left axillary lymphadenopathy and hepatosplenomegaly. 
ESR was 88 mm/h, and CRP concentration was 131 mg/L. 
CT images showed lung scarring, splenomegaly, pericar-
dial effusion, and multifocal adenopathy of the left axilla, 
mediastinum, celiac, periaortic, retroperitoneal, and mesen-
teric regions. Culture of excised axillary lymph node grew 
S. epidermidis, and G. bethesdensis (100% match to the G. 
bethesdensis type strain by full 16S rRNA gene sequenc-
ing, ≈1,500 bp). Etest of G. bethesdensis isolate showed the 
following MICs in μg/mL: tobramycin (MIC = 4), ceftri-
axone (MIC = 32), doxycycline (MIC = 8), trimethoprim/
sulfamethoxazole (MIC = 2), and tigecycline (MIC = 16).
The patient was empirically administered vancomy-
cin and ceftriaxone and was discharged with ceftriaxone, 
doxycycline, prophylactic trimethoprim/sulfamethoxazole, 
and itraconazole. His medication was eventually switched 
to cefdinir along with CGD prophylaxis. After 15 months, 
inflammatory markers and left neck and supraclavicular 
lymphadenopathy had improved but had not yet normalized.
Discussion
We have identified a total of 12 infections caused by 3 
methylotroph bacteria in patients with CGD: 2 A. metha-
nolica, 1 M. lusitanum, and 9 G. bethesdensis infections. 
Infections caused by A. methanolica and G. bethesdensis 
have been reported only for patients with CGD, whereas 
M. lusitanum in a patient without CGD undergoing che-
motherapy for leukemia has been reported (10). These 
observations suggest that Nox2-based complex activity 
(superoxide production) is critical for protection against 
methylotroph infections. Consistent with this hypothesis, 
previous studies have demonstrated that G. bethesdensis 
persists in Nox2-based complex-deficient myeloid cells 
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and is largely resistant to oxygen-independent microbicidal 
activity (11,12).
Methylotroph infections in CGD patients typically re-
sult in elevated inflammatory markers and lymphadenopa-
thy, which may progress to necrotizing lymphadenitis with 
or without abscess formation. The clinical course may be 
protracted because of infection persistence, antimicrobial 
drug resistance, and relapse. Culturing these bacteria is 
difficult, requiring atypical media and prolonged incuba-
tion. These infections have not been fatal for patients in 
North and Central America, but G. bethesdensis infections 
in patients from Portugal and Spain (5) have caused fa-
tal meningitis and bacteremia, respectively. The different 
clinical courses and outcomes for these patients compared 
with those in North and Central America suggest that the 
G. bethesdensis strain from Europe may be more virulent; 
animal studies are needed to explore this possibility. Fur-
thermore, the strains isolated in Spain and Portugal showed 
only a 99.7% match with the 16S rRNA sequence of the 
type strain from North America, whereas most strains from 
North and Central America showed a 100% match with the 
type strain. Moreover, the strain from Europe displayed 
more in vitro resistance to antimicrobial agents and was 
resistant to colistin, most β-lactams, and quinolones (5). 
Although the value and accuracy of in vitro susceptibil-
ity testing for G. bethesdensis are unknown and may lack 
predictive value, the clinical and laboratory differences be-
tween G. bethesdensis strains from the United States and 
Europe may have substantial implications for therapy.
The facultative methylotrophs we report were difficult 
to culture; their correct identification required non–culture-
based techniques, such as 16S rRNA gene sequencing, and 
a high index of suspicion. Application of 16S rRNA se-
quencing and molecular probes to target tissues may iden-
tify previously unrecognized bacteria, which may accom-
pany and possibly facilitate methylotroph infections.
G. bethesdensis is a gram-negative, aerobic, oxidase-
negative, and catalase positive bacillus. Culture is facili-
tated by specimen centrifugation and plating on buffered 
charcoal yeast extract agar or solid mycobacterial media; 
incubation takes up to 2 weeks (6). A. methanolica is a 
gram-negative, aerobic, acid-tolerant, catalase-positive, 
urease-positive, oxidase-positive, non–spore-forming, and 
nonmotile rod-shaped bacterium (13). It forms tan colo-
nies in <5 days on chocolate agar and grows well on po-
tato dextrose agar. M. lusitanum is a vacuolated gram-neg-
ative aerobic rod that is positive for indophenol oxidase, 
catalase, and urease and produces a pink pigment. It also 
reduces nitrate and assimilates malate (10). Methanol de-
hydrogenase serology is currently under investigation as a 
potential supportive diagnostic or prognostic tool for track-
ing methylotroph infections, particularly those caused by 
G. bethesdensis (14).
Management of methylotroph infections is often pro-
longed and may require combination antimicrobial drug 
therapy and surgery. Drug susceptibilities are difficult to 
determine and interpret. In vitro, G. bethesdensis is typical-
ly resistant to most penicillins, cephalosporins, carbapen-
ems, and quinolones, but it is sometimes susceptible in 
vitro to ceftriaxone, aminoglycosides, doxycycline, and tri-
methoprim/sulfamethoxazole; combinations of these drugs 
have helped achieve initial resolution (6). Although anti-
microbial drug susceptibilities for A. methanolica are not 
well defined, infections seemed to respond to combinations 
including meropenem, ciprofloxacin, gentamicin, doxycy-
cline, and trimethoprim/sulfamethoxazole. M. lusitanum 
seems to be susceptible to aminoglycosides, cephalospo-
rins, ciprofloxacin, piperacillin/tazobactam, and imipenem 
but not to meropenem, trimethoprim/sulfamethoxazole, or 
aztreonam. The role of surgery in treating methylotroph 
infections has not been defined, but its successful use in 
several cases is noteworthy.
In conclusion, methylotrophs are environmental or-
ganisms that can cause necrotizing infections in patients 
with CGD. Infectious prodromes and clinical courses may 
be prolonged. Diagnosis requires a high index of suspicion 
so that appropriate culture conditions and culture-indepen-
dent techniques can be established for diagnosis. The diffi-
culty of growing methylotrophs from infected lesions gives 
pause for the use of the label “sterile inflammation” with 
regard to CGD patients. Methylotrophs should be aggres-
sively sought as the cause of chronic necrotizing infections 
in patients with CGD.
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